ARYYX
Price
$14.58
Change
+$0.02 (+0.14%)
Updated
Jun 5 closing price
Net Assets
798.7M
CSFZX
Price
$58.56
Change
-$0.01 (-0.02%)
Updated
Jun 5 closing price
Net Assets
2.31B
Interact to see
Advertisement

ARYYX vs CSFZX

Header iconARYYX vs CSFZX Comparison
Open Charts ARYYX vs CSFZXBanner chart's image
ARYYX vs CSFZX Comparison Chart in %
View a ticker or compare two or three
VS
ARYYX vs. CSFZX commentary
Jun 06, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARYYX is a Buy and CSFZX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
CSFZX has more cash in the bank: 2.32B vs. ARYYX (799M). CSFZX (3.24) and ARYYX (3.10) have matching dividends . ARYYX was incepted earlier than CSFZX: ARYYX (9 years) vs CSFZX (12 years). CSFZX (0.84) is less costly to investors than ARYYX (0.76). ARYYX is a more actively managed with annual turnover of: 137.00 vs. CSFZX (57.00). ARYYX (0) and CSFZX (0) have matching initial minimum investment requirements. ARYYX annual gain was more profitable for investors over the last year : 13.69 vs. CSFZX (11.78). ARYYX return over 5 years is better than : 10.83 vs. CSFZX (7.51).
ARYYXCSFZXARYYX / CSFZX
Total Expense Ratio0.760.8490%
Annual Report Gross Expense Ratio0.760.8490%
Fund Existence9 years12 years-
Gain YTD8.7387.369119%
Front LoadN/AN/A-
Min. Initial Investment00-
Min. Initial Investment IRAN/AN/A-
Net Assets799M2.32B35%
Annual Yield % from dividends3.103.2496%
Returns for 1 year13.6911.78116%
Returns for 3 years38.4229.11132%
Returns for 5 years10.837.51144%
Returns for 10 yearsN/A53.51-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ODINX107.36N/A
N/A
Invesco Discovery R
AIEMX16.49N/A
N/A
Alger Emerging Markets I
HGHCX25.05N/A
N/A
Hartford Healthcare C
JMVCX16.43N/A
N/A
Janus Henderson Mid Cap Value C
DFDMX33.07-0.37
-1.11%
DF Dent Midcap Growth Investor